Alli is the over-the-counter half-dose version of orlistat that blocks fat absorption
A landmark 2025 meta-analysis published in the Journal of the American College of Cardiology pooled 21 randomized controlled trials covering 99,599 patients and found high-certainty evidence that GLP-1 receptor agonists produced: 12% reduction in all-cause death (IRR 0.88
This prevents doses from being too close together, which helps avoid unwanted side effects
For years, the question of whether a daily pill could ever match the efficacy of a weekly injection was largely theoretical
Everyone responds differently to the medication, so while some may see quick results, for others, the changes may be slower and more gradual
moreover, these findings did not appear to be secondary to alterations in the electrophysiological properties of the cardiac myocyte